Is This Dark-Horse Coronavirus Stock a Threat to Gilead Sciences?
Synairgen's (LSE: SNG) stock skyrocketed on Monday amid news that the largely unknown British respiratory therapeutics company had demonstrated in a phase 2 clinical trial that its inhalable drug SNG001 reduced the chances of coronavirus patients needing a ventilator by a stunning 79%. While the results are still preliminary and need robust third-party confirmation, investors are already curious about whether SNG001 poses a threat to established competitors in the coronavirus therapeutics space, like Gilead Sciences (NASDAQ: GILD) and its antiviral drug remdesivir. In a nutshell, there's a lot to be hopeful about when it comes to Synairgen's new therapy, but that doesn't mean you should rush to sell your Gilead shares.